Snail Pharma Industry

Suzhou Snail Pharma Industry Co., Ltd. is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the discovery and development of innovative small molecule drugs for metabolic and inflammatory diseases. The company leverages its proprietary medicinal chemistry platform to develop oral alternatives to injectable peptide therapies, particularly targeting the GLP-1 and GIP pathways. Its lead candidate, SNP-630, is a potent oral GLP-1 receptor agonist currently undergoing Phase 2 clinical trials for obesity and type 2 diabetes. Snail Pharma's pipeline also includes multi-receptor agonists and treatments for NASH and autoimmune disorders. Backed by top-tier venture capital firms, the company aims to provide more accessible and convenient treatment options for chronic metabolic conditions globally.